ArticleInterdisciplinary cardiovascular and thoracic surgery2026
Pulmonary Metastasectomy for Head and Neck Squamous Cell Carcinoma in the Modern Treatment Era.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesPulmonary metastasectomy (PM) has been a viable treatment option for metastatic head and neck squamous cell carcinoma (HNSCC). In recent years, advances in systemic therapy and multidisciplinary cancer management, including immune checkpoint inhibitors (ICIs), have changed the treatment landscape of advanced or recurrent head and neck cancer.
methodsWe retrospectively reviewed 44 patients who underwent complete resection for pulmonary metastases from HNSCC between 2008 and 2021. To minimize the risk of including primary lung cancer, 8 patients were excluded based on predefined clinical criteria, resulting in a final cohort of 36 patients for analysis. Patients were divided into the early (2008-2016) and late (2017-2021) period groups. Relapse-free survival (RFS), overall survival (OS), and prognostic factors were assessed.
resultsThe 5-year RFS and OS for all patients were 41% and 67%, respectively. Postoperative chemotherapy was associated with better RFS, and age ≤65 years with better OS. ICIs were administered to 1 patient in the early period group and 7 in the late period group during the clinical course (P = .005). The 5-year RFS and OS were 42% vs 40% and 55% vs 87% in the early and late period groups, respectively. While RFS was comparable, OS tended to be better in the late period group, although the difference was not statistically significant.
conclusionsPM is associated with favourable long-term outcomes in patients with HNSCC. Given its potential for long-term survival and diagnostic value, PM remains an important treatment option for HNSCC in the modern treatment era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.